Skip to main content

Table 1 Demographics and patient characteristics (safety set)

From: A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria

All patients

 

800:640 (N = 143)

800:960 (N = 148)

800:1440 (N = 146)

Total (N = 437)

Africa

Number (n)

116

121

118

355

Age (years) (derived)

Median

3.30

3.20

2.90

3.10

(Min., max.)

(0.5, 54.3)

(0.8, 44.6)

(0.5, 37.7)

(0.5, 54.3)

  > 15.0 years

n (%)

15 (12.9)

16 (13.2)

14 (11.9)

45 (12.7)

  > 5.0 to ≤ 15.0 years

n (%)

7 (6.0)

7 (5.8)

8 (6.8)

22 (6.2)

  > 2.0 to ≤ 5.0 years

n (%)

69 (59.5)

72 (59.5)

70 (59.3)

211 (59.4)

  ≥ 0.5 to ≤ 2.0 years

n (%)

25 (21.6)

26 (21.5)

26 (22.0)

77 (21.7)

 Male

n (%)

56 (48.3)

63 (52.1)

70 (59.3)

189 (53.2)

Vietnam

n

27

27

28

82

Age (years) (derived)

Median

27.30

27.30

28.60

27.45

(Min., max.)

(12.5, 48.5)

(9.7, 60.0)

(13.3, 57.6)

(9.7, 60.0)

  > 15.0 years

n (%)

26 (96.3)

26 (96.3)

27 (96.4)

79 (96.3)

  > 5.0 to ≤ 15.0 years

n (%)

1 (3.7)

1 (3.7)

1 (3.6)

3 (3.7)

  > 2.0 to ≤ 5.0 years

n (%)

0

0

0

0

  ≥ 0.5 to ≤ 2.0 years

n (%)

0

0

0

0

 Male

n (%)

27 (100.0)

22 (81.5)

28 (100.0)

77 (93.9)

  1. n number of patients in each category/%)